Lactated Ringers

Manufacturer
Hospira, Inc.
Effective date
2020-07-10
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
18
Source
legacy-cache
Hydrated at
2026-08-01 23:21:53

Label at a glance#

ProductLactated Ringers and Dextrose
Active ingredientSODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, DEXTROSE MONOHYDRATE
Label structure16 sections

Indications and uses

These solutions are indicated for parenteral replacement of extracellular losses of fluid and electrolytes, with or without minimal carbohydrate calories, as required by the clinical condition of the patient.

Dosage and administration

The dose is dependent upon the age, weight and clinical condition of the patient.   As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Additives may be incompatible. Consult with pharmacist, if available. When...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Flexible Plastic Container

Rx only

DESCRIPTION

DESCRIPTION SECTION

These products are sterile, nonpyrogenic solutions each containing isotonic concentrations of electrolytes (with or without dextrose) in water for injection. The solutions containing dextrose and electrolytes are hypertonic; those containing only electrolytes are isotonic. They are administered by intravenous infusion for parenteral replacement of extracellular losses of fluid and electrolytes, with or without minimal carbohydrate calories.

Each 100 mL of Lactated Ringer's Injection, USP contains sodium chloride 600 mg, sodium lactate, anhydrous 310 mg, potassium chloride 30 mg and calcium chloride, dihydrate 20 mg. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. A liter provides 9 calories (from lactate), sodium (Na+), 130 mEq, potassium (K+) 4 mEq, calcium (Ca++) 3 mEq, chloride (Cl−) 109 mEq and lactate [CH3CH(OH) COO−] 28 mEq. The electrolyte content is isotonic (273 mOsmol/liter, calc.) in relation to the extracellular fluid (approx. 280 mOsmol/liter). The pH of the solution is 6.6 (6.0 − 7.5).

   Each 100 mL of Lactated Ringer's and 5% Dextrose Injection, USP contains dextrose, hydrous 5 g plus the same ingredients and mEq values as Lactated Ringer's Injection, USP (contains only hydrochloric acid for pH adjustment). A liter provides 179 calories (from dextrose and lactate) and has a hypertonic osmolar concentration of 525 mOsmol (calc.). The pH is 4.9 (4.0 − 6.5).

   The solutions contain no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and each is intended only for use as a single-dose injection. When smaller doses are required the unused portion should be discarded.

   The solutions are parenteral fluid, nutrient and/or electrolyte replenishers.

   Dextrose, USP is chemically designated D-glucose, monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. It has the following structural formula:

structural formula dextrosestructural formula dextrose

  Calcium Chloride, USP is chemically designated calcium chloride, dihydrate (CaCl2 • 2 H2O), white fragments or granules freely soluble in water.

   Potassium Chloride, USP is chemically designated KCl, a white granular powder freely soluble in water.

  Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.


    Sodium Lactate, USP is chemically designated monosodium lactate [CH3CH(OH)COONa], a 60% aqueous solution miscible in water.

It has the following structural formula:

structural formula sodium lactatestructural formula sodium lactate

    Water for Injection, USP is chemically designated H2O.

  The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of their chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

When administered intravenously, these solutions provide sources of water and electrolytes with or without minimal carbohydrate calories. Their electrolyte content resembles that of the principal ionic constituents of normal plasma and the solutions therefore are suitable for parenteral replacement of extracellular losses of fluid and electrolytes, with or without carbohydrate calories.

  Solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories.

   Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.

   Calcium chloride in water dissociates to provide calcium (Ca++) and chloride (Cl−) ions. They are normal constituents of the body fluids and are dependent on various physiologic mechanisms for maintenance of balance between intake and output. Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

  Potassium chloride in water dissociates to provide potassium (K+) and chloride (Cl−) ions. Potassium is found in low concentration in plasma and extracellular fluids (3.5 to 5.0 mEq/liter in a healthy adult). It is the chief cation of body cells (160 mEq/liter of intracellular water). Potassium plays an important role in electrolyte balance. Normally about 80 to 90% of the potassium intake is excreted in the urine; the remainder in the stools and to a small extent, in the perspiration. The kidney does not conserve potassium well so that during fasting or in patients on a potassium-free diet, potassium loss from the body continues resulting in potassium depletion.

   Sodium chloride in water dissociates to provide sodium (Na+) and chloride (Cl−) ions. Sodium (Na+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl−) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na+) and chloride (Cl−) are largely under the control of the kidney which maintains a balance between intake and output.

   Sodium lactate provides sodium (Na+) and lactate (C3H503 −) ions. The lactate anion is in equilibrium with pyruvate and has an alkalizing effect resulting from simultaneous removal by the liver of lactate and hydrogen ions. In the liver, lactate is metabolized to glycogen which is ultimately converted to carbon dioxide and water by oxidative metabolism. The sodium (Na+) ion combines with bicarbonate ion produced from carbon dioxide of the body and thus retains bicarbonate to combat metabolic acidosis (bicarbonate deficiency). The normal plasma level of lactate ranges from 0.9 to 1.9 mEq/liter.

   Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).

  Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

These solutions are indicated for parenteral replacement of extracellular losses of fluid and electrolytes, with or without minimal carbohydrate calories, as required by the clinical condition of the patient.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Solutions containing lactate are NOT FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS.

WARNINGS

WARNINGS SECTION

Solutions containing calcium ions should not be administered simultaneously through the same administration set as blood because of the likelihood of coagulation.

  Solutions which contain potassium should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.

  Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

   In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.

   Solutions containing lactate ions should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care where there is an increased level or an impaired utilization of lactate ions, as in severe hepatic insufficiency.

   The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions.

  The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

PRECAUTIONS

PRECAUTIONS SECTION

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

   Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

   Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.

   Potassium containing solutions should be used with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.

  Solutions containing lactate ions should be used with caution as excess administration may result in metabolic alkalosis.

  Do not administer unless solution is clear and container is undamaged. Discard unused portion.

PREGNANCY SECTION

Pregnancy Category C. Animal reproduction studies have not been conducted with Ringer's Injection, USP, Ringer's and Dextrose Injection, USP, Lactated Ringer's Injection, USP or Lactated Ringer's and Dextrose Injection, USP. It is also not known whether these injections can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. These injections should be given to a pregnant woman only if clearly needed.

PEDIATRIC USE SECTION

Pediatric Use: The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.

  Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolarity and possible intracerebral hemorrhage.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

  If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

OVERDOSAGE SECTION

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dose is dependent upon the age, weight and clinical condition of the patient.

  As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

Drug Interactions

DRUG INTERACTIONS SECTION

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

  The presence of calcium limits their compatibility with certain drugs that form precipitates of calcium salts, and also prohibits their simultaneous infusion through the same administration set as blood because of the likelihood of coagulation.

   Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

INSTRUCTIONS FOR USE

SPL UNCLASSIFIED SECTION

To Open: 

Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below before preparing for administration. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

To Add Medication 

  1. Prepare additive port.
  2. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication.
  3. The additive port may be protected by covering with an additive cap.
  4. Mix container contents thoroughly.

Preparation for Administration 

(Use aseptic technique)

  1. Close flow control clamp of administration set.
  2. Remove cover from outlet port at bottom of container.
  3. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: See full directions on administration set carton.
  4. Suspend container from hanger.
  5. Squeeze and release drip chamber to establish proper fluid level in chamber.
  6. Open flow control clamp and clear air from set. Close clamp.
  7. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
  8. Regulate rate of administration with flow control clamp.

WARNING: DO NOT USE FLEXIBLE CONTAINER IN SERIES CONNECTIONS. 

HOW SUPPLIED

HOW SUPPLIED SECTION

These solutions are supplied in single-dose flexible plastic containers as follows:

NDC No.
Product Name
Container Size (mL)

0409-7953-02

Lactated Ringer's Inj., USP

250

0409-7953-03

Lactated Ringer's Inj., USP

500
0409-7953-09

Lactated Ringer's Inj., USP

1000

0409-7929-03

Lactated Ringer's and 5% Dextrose Inj., USP

500

0409-7929-09

Lactated Ringer's and 5% Dextrose Inj., USP

1000

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.

Revised: July, 2009

 

Printed in USA                            EN-2203

Hospira, Inc., Lake Forest, IL 60045 USA

IM-0036

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

iv bag ndc 0409-7929-09iv bag ndc 0409-7929-09

PRINCIPAL DISPLAY PANEL - 1000 mL Bag Overwrap - NDC 0409-7929-09

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

TO OPEN TEAR AT NOTCH

2
HDPE

DO NOT REMOVE FROM OVERWRAP UNTIL READY FOR USE. AFTER REMOVING
THE OVERWRAP, CHECK FOR MINUTE LEAKS BY SQUEEZING CONTAINER FIRMLY.
IF LEAKS ARE FOUND, DISCARD SOLUTION AS STERILITY MAY BE IMPAIRED.
RECOMMENDED STORAGE: ROOM TEMPERATURE (25°C). AVOID EXCESSIVE
HEAT. PROTECT FROM FREEZING. SEE INSERT.
98-4321-R14-3/98

PRINCIPAL DISPLAY PANEL - 1000 mL Bag Overwrap - NDC 0409-7929-09
PRINCIPAL DISPLAY PANEL - 1000 mL Bag Overwrap - NDC 0409-7929-09

IM-0611

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

iv bag ndc 0409-7953-09iv bag ndc 0409-7953-09

PRINCIPAL DISPLAY PANEL - 1000 mL Bag Overwrap - NDC 0409-7953-09

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

TO OPEN TEAR AT NOTCH

2
HDPE

DO NOT REMOVE FROM OVERWRAP UNTIL READY FOR USE. AFTER REMOVING
THE OVERWRAP, CHECK FOR MINUTE LEAKS BY SQUEEZING CONTAINER FIRMLY.
IF LEAKS ARE FOUND, DISCARD SOLUTION AS STERILITY MAY BE IMPAIRED.
RECOMMENDED STORAGE: ROOM TEMPERATURE (25°C). AVOID EXCESSIVE
HEAT. PROTECT FROM FREEZING. SEE INSERT.
98-4321-R14-3/98

PRINCIPAL DISPLAY PANEL - 1000 mL Bag Overwrap - NDC 0409-7953-09
PRINCIPAL DISPLAY PANEL - 1000 mL Bag Overwrap - NDC 0409-7953-09

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0409-7929-03ML - Milliliter0409-7929a84a09b8-1a2c-412b-8cad-97e8bc7e2bb912012-07-24
0409-7929-09ML - Milliliter0409-79291a811e63-cd7d-4ee2-8932-715bd8ed4afc12012-07-24
0409-7953-02ML - Milliliter0409-79539bf7762e-8fbe-49f9-a789-bffceef413c412012-07-24
0409-7953-03ML - Milliliter0409-79539748f1cf-c03d-4db4-932e-5950d6f56e1b12012-07-24
0409-7953-09ML - Milliliter0409-7953b8a9485e-4d62-4310-9f2e-65a8554681a812012-07-24
0409-7953-30ML - Milliliter0409-7953588d1b67-8162-4996-b4a7-6cc61b44a40312012-07-24
0409-7953-48ML - Milliliter0409-795378e026c1-54a0-4101-bcc8-fd108851993112012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CALCIUM CHLORIDEACTIVE INGREDIENTM4I0D6VV5M14
DEXTROSE MONOHYDRATEACTIVE INGREDIENTLX22YL083G14
POTASSIUM CHLORIDEACTIVE INGREDIENT660YQ98I1014
SODIUM CHLORIDEACTIVE INGREDIENT451W47IQ8X14
SODIUM LACTATEACTIVE INGREDIENTTU7HW0W0QT14
ANHYDROUS DEXTROSEACTIVE MOIETY5SL0G7R0OK14
CHLORIDE IONACTIVE MOIETYQ32ZN4869814
LACTIC ACIDACTIVE MOIETY33X04XA5AT14
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CB14
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I14

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0409-79290409-7929-03, 0409-7929-09
0409-79530409-7953-02, 0409-7953-03, 0409-7953-09

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 6 · 322 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IELIXIR / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / RETROBULBARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IDISC / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPASTE / DENTAL0.6 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / PARENTERALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTERSTITIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, ORALLY DISINTEGRATING / ORAL1 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / SUBCONJUNCTIVALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / PERIDURALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRACAVITARYADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBLIQUID / INTRAMUSCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / EXTRACORPOREALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / PERINEURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, EXTENDED RELEASE / ORAL13 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / AURICULAR (OTIC)0.8 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / OPHTHALMIC0.05 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICREAM, AUGMENTED / TOPICAL6 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACAVITARYADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / TOPICAL39 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS5 mgExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRAPLEURALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBGEL, METERED / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / URETERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRADERMALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, COATED / ORALNAExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / DENTALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER, FOR SUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, COATED PELLETS / ORAL0.01 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / EXTRACORPOREALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRAVESICAL157 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / ORAL400 mgExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR5 mgExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 2 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINERCALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N017608-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N017608-001DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPRLD, Approved before 19823a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09N017608-001AP1c2088c7a36db…
2026-09-14 22:38:342026-08N017608-001AP184e616aacf4f…
2026-08-18 06:07:402026-07N017608-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N017608-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N017608-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08N017608-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N017608-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N017608-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N017608-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N017608-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N017608-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N017608-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N017608-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N017608-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N017608-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N017608-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N017608-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N017608-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N017608-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N017608-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N017608-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N017608-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N017608-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N017608-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03N017608-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N017608-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N017608-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N017608-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09N017608-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07N017608-001AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N017608-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N017608-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N017608-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N017608-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N017608-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N017608-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N017608-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05N017608-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01N017608-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N017608-001AP13a93d1ddd44b…

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N017641-001LACTATED RINGER'S IN PLASTIC CONTAINERCALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N017641-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N017641-001LACTATED RINGER'S IN PLASTIC CONTAINER20MG/100ML;30MG/100ML;600MG/100ML;310MG/100MLINJECTABLE / INJECTIONAPApproved before 19823a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09N017641-001AP1c2088c7a36db…
2026-09-14 22:38:342026-08N017641-001AP184e616aacf4f…
2026-08-18 06:07:402026-07N017641-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N017641-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N017641-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08N017641-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N017641-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N017641-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N017641-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N017641-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N017641-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N017641-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N017641-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N017641-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N017641-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N017641-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N017641-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N017641-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N017641-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N017641-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N017641-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N017641-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N017641-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N017641-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03N017641-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N017641-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N017641-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N017641-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09N017641-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07N017641-001AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N017641-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N017641-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N017641-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N017641-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N017641-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N017641-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N017641-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05N017641-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01N017641-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N017641-001AP13a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
39230f8c-4492-4860-be1c-5a61f454cbcdeb269566-5024-4495-fb86-db0339bd04882020-07-10Warnings, Adverse reactionsExact identifier
spl id: 39230f8c-4492-4860-be1c-5a61f454cbcd
spl set id: eb269566-5024-4495-fb86-db0339bd0488

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.